Continuous Production of Influenza VLPs Using IC‐BEVS and Multi‐Stage Bioreactors
Biotechnology and Bioengineering · 2025
DOI: 10.1002/bit.28925 ↗At a glance
Journal article in Biotechnology and Bioengineering, 2025. Written by Ricardo Correia and 7 co-authors. Institution: Instituto de Biologia Experimental e Tecnológica (iBET), Oeiras, Portugal. Major MEDLINE topics: Bioreactors, Baculoviridae, Hemagglutinin Glycoproteins, Influenza Virus, Vaccines, Virus-Like Particle. Cited 10 times so far (Crossref); 39 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: This work was supported by Fundação para a Ciência e a Tecnologia and European Commission..
Abstract (original language)
The insect cell‐baculovirus expression vector system (IC‐BEVS) has been an asset to produce biologics for over 30 years. With the current trend in biotechnology shifting toward process intensification and integration, developing intensified processes such as continuous production is crucial to hold this platform as a suitable alternative to others. However, the implementation of continuous production has been hindered by the lytic nature of this expression system and the process‐detrimental virus passage effect. In this study, we implemented a multi‐stage bioreactor setup for continuous production of influenza hemagglutinin‐displaying virus‐like particles (HA‐VLPs) using IC‐BEVS. A setup consisting of one Cell Growth Bioreactor simultaneously feeding non‐infected insect cells to three parallel Production Bioreactors operated at different residence times (RT) (18, 36, and 54 h) was implemented; Production Bioreactors were continuously harvested. Two insect cell lines (neutral pH–adapted High Five and Sf 9) and two recombinant baculovirus (rBAC) constructs (one that originates from a bacmid, rBAC bacmid , and another of non‐bacteria origin, rBAC flashbac ) were tested. Combining rBAC flashbac with Sf 9 cells was the most efficient approach, allowing consistent HA‐VLPs titers (34 ± 14 HA titer/mL) and rBAC titers (10 8 –10 9 pfu/mL) throughout the period of continuous operation (20 days). Cell growth kinetics and viability varied across RT, and higher RT was associated with increased expression of HA‐VLPs, independent of the cell line and rBAC used; RT of 54 h allowed to maximize titers. The presence of particles resembling HA‐VLPs was confirmed by transmission electron microscopy throughout the continuous operation. This work showcases the implementation of a process for continuous production of a promising class of biotherapeutics (i.e., VLPs), and paves the way for establishing continuous, integrated setups using the IC‐BEVS expression system.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Instituto de Biologia Experimental e Tecnológica (iBET), Oeiras, Portugal.
- Instituto de Tecnologia Química e Biológica António Xavier (ITQB NOVA), Universidade Nova de Lisboa, Oeiras, Portugal.
- Laboratory of Virology, Wageningen University & Research, Wageningen, the Netherlands.
ORCID profiles: Ricardo Correia, Bárbara Fernandes
Funding
- This work was supported by Fundação para a Ciência e a Tecnologia and European Commission.
Cite
APA
Correia, R., Zotler, T., Ferraz, F., Fernandes, B., Graça, M., Pijlman, G. P., Alves, P. M., & Roldão, A. (2025). Continuous Production of Influenza VLPs Using IC‐BEVS and Multi‐Stage Bioreactors. Biotechnology and Bioengineering. https://doi.org/10.1002/bit.28925
Vancouver
Correia R, Zotler T, Ferraz F, Fernandes B, Graça M, Pijlman GP, et al. Continuous Production of Influenza VLPs Using IC‐BEVS and Multi‐Stage Bioreactors. Biotechnology and Bioengineering. 2025. doi:10.1002/bit.28925
BibTeX
@article{Correia2025,
author = {Correia, Ricardo and Zotler, Taja and Ferraz, Francisco and Fernandes, Bárbara and Graça, Miguel and Pijlman, Gorben P and Alves, Paula M and Roldão, António},
title = {Continuous Production of Influenza VLPs Using IC‐BEVS and Multi‐Stage Bioreactors},
journal = {Biotechnology and Bioengineering},
year = {2025},
doi = {10.1002/bit.28925}
}
EUVIMED